Expert Interview
A look at the potential of menin inhibitors for patients with acute myeloid leukemias, specifically Syndax Pharmaceuticals' revumenib and how it compares to Kura's ziftomenib.
Ticker(s): SNDXInstitution: Fred Hutchinson Cancer Center
- Professor in the clinical research division, Endowed Chair for Cancer Research at Fred Hutchinson Cancer Center & Professor of Medicine at the University of Washington.
- Currently manages over 50 patients with AML.
- Research involves developing improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate AML stem cells.
How optimistic are you about menin inhibitors as a treatment option for your patients with AML?
Added By: sara_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of revumenib, what would it be and why?
Added By: sara_adminIn your opinion, How does revumenib compare to Kura's menin inhibitor, ziftomenib?
Added By: sara_adminHow significant are the differences in treatment outcomes between AML subtypes (KMT2A-rearranged vs. NPM1-mutated) when treated with Revumenib or Ziftomenib?
What insights are emerging from trials using menin inhibitors in combination with chemotherapy or VENAZA in both newly diagnosed and relapsed/refractory AML patients?
What are the key challenges in interpreting early-phase trial data for menin inhibitors, especially given the small sample sizes and high initial response rates?
How do safety concerns, such as differentiation syndrome and QT prolongation, impact the potential clinical adoption of menin inhibitors?
Added By: slingshot_insightsHow might the first-to-market advantage of Revumenib influence its adoption and preference among clinicians compared to Ziftomenib?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
